Calcipotriol
| Clinical data | |
|---|---|
| Trade names | Daivonex, others |
| Other names | calcipotriene (USAN US) |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a608018 |
| License data | |
| Pregnancy category |
|
| Routes of administration | topical |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 5 to 6% |
| Metabolism | Liver |
| Excretion | Biliary |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.119.473 |
| Chemical and physical data | |
| Formula | C27H40O3 |
| Molar mass | 412.614 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (what is this?) (verify) | |
Calcipotriol, also known as calcipotriene and sold under the brand name Dovonex among others, is a synthetic derivative of calcitriol, a form of vitamin D. It is used in the treatment of psoriasis.
It was patented in 1985 and approved for medical use in 1991. It is on the World Health Organization's List of Essential Medicines.
Calcipotriol is also available with the synthetic corticosteroid betamethasone dipropionate as the fixed-dose combination medication calcipotriol/betamethasone dipropionate for the treatment of plaque psoriasis.